Skip to content
value.today
Nurix, Inc. logo

Nurix, Inc.

Formerly Kura Therapeutics, Inc.

Total raised
$145 M
4 rounds on record
Latest round
$120 M
Mar 2020
First round on record
Apr 2012
Today
Went public
See the company page

Nurix, Inc. is listed today as Nurix Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Nurix, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2020$120 MNo. 4$50 to $250 million

Nurix, Inc.: Raise no. 4, Mar 2020

Investors in this round

23 investors had bought by the notice of Mar 26, 2020: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Nurix, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$120 M of $120 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arthur Sands · Executive Officer, Director
  • Christine Ring · Executive Officer
  • Hans van Houte · Executive Officer
  • David Lacey · Director
  • Jeff Tong · Director
  • Julia Gregory · Director
  • Leon Chen · Director
  • Lori Kunkel · Director
  • Robert Tjian · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christine Ring, Secretary. Source: SEC Form D, newest notice filed Mar 26, 2020. Read the notice at the SEC.

equitySEC
Sep 2015$17 MNo. 3$10 to $50 million

Nurix, Inc.: Raise no. 3, Sep 2015

Investors in this round

1 investor had bought by the notice of Sep 18, 2015: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Nurix, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $17 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arthur T. Sands · Executive Officer, Director
  • Timothy Kutzkey · Executive Officer, Director
  • David Goeddel · Director
  • Mark Goldsmith · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Proceeds are to be used for working capital.”

Signed by Michael E. Tenta, Secretary. Source: SEC Form D, newest notice filed Sep 18, 2015. Read the notice at the SEC.

equitySEC
Dec 2013$2 MNo. 2$2 to $10 million

Nurix, Inc.: Raise no. 2, Dec 2013

Investors in this round

2 investors had bought by the notice of Jan 2, 2014: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Nurix, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $25 M offered; $23 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark Goldsmith · Executive Officer, Director
  • Timothy Kutzkey · Executive Officer, Director
  • David Goeddel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Proceeds are to be used for working capital.”

Signed by Michael E. Tenta, Secretary. Source: SEC Form D, newest notice filed Jan 2, 2014. Read the notice at the SEC.

equitySEC
Apr 2012$5 MNo. 1$2 to $10 million

Nurix, Inc.: Raise no. 1, Apr 2012

Investors in this round

4 investors had bought by the notice of Mar 28, 2013: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Nurix, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mark Goldsmith · Executive Officer, Director
  • Timothy Kutzkey · Executive Officer, Director
  • David Goeddel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Proceeds are to be used for working capital.”

Signed by Michael E. Tenta, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Mar 28, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Nurix Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: Collaboration revenue $53.98 million (64%), License revenue $30 million (36%).

    Annual report (SEC XBRL) · Nov 2025

  • Nurix, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2020).

    SEC Form D · Mar 2020

  • The industry group it chose in its notices: Other.

    SEC Form D · Mar 2020

Products and services#

No products or services of Nurix, Inc. are on record.

Investors#

13 named in official filings. Open an investor to see everything it has backed.

Investors in Nurix, Inc.
InvestorKindAmountRoundRoleSource
Column Group GP, LPFund or asset managernot statednot statedHeld Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Column Group II GP, LPFund or asset managernot statednot statedHeld Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Column Group II, LPFund or asset managernot statednot statedHeld Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Column Group L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Ponoi Capital II, LPFund or asset managernot statednot statedHeld Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Ponoi Capital, LPFund or asset managernot statednot statedHeld Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Ponoi II Management, LLCFund or asset managernot statednot statedHeld Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Ponoi Management, LLCFund or asset managernot statednot statedHeld Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Redmile Group, LLCFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Third Rock Ventures GP III, L.P.Venture capitalnot statednot statedHeld Series B and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Third Rock Ventures III, L.P.Venture capitalnot statednot statedHeld Series B and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
TRV GP III, LLCOthernot statednot statedHeld Series B and D preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 23 investors.

Largest shareholders today

Institutions holding Nurix Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Nurix, Inc.
NameRoleNamed in
Arthur SandsExecutive officerMar 2020
Christine RingExecutive officerMar 2020
Hans van HouteExecutive officerMar 2020
Arthur T. SandsExecutive officerSep 2015
Timothy KutzkeyExecutive officerSep 2015
Mark GoldsmithExecutive officerJan 2014
Arthur SandsDirectorMar 2020
David LaceyDirectorMar 2020
Jeff TongDirectorMar 2020
Julia GregoryDirectorMar 2020
Leon ChenDirectorMar 2020
Lori KunkelDirectorMar 2020
Robert TjianDirectorMar 2020
Arthur T. SandsDirectorSep 2015
David GoeddelDirectorSep 2015
Mark GoldsmithDirectorSep 2015
Timothy KutzkeyDirectorSep 2015

About

Company in San Francisco, United States.

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.